Availability on request
RetatrutideRetatrutide (development code LY3437943) is a triple receptor agonist currently under development that targets GIP, GLP-1, and glucagon (GCG) receptors simultaneously. It is primarily being investigated for the treatment of obesity, overweight, and related metabolic diseases. Key advantage: significant weight loss.
10 mg · 10 vialsAvailability on request
TirzepatideTirzepatide is a once-weekly GIP+GLP-1 dual receptor agonist currently used primarily to treat type 2 diabetes and to assist with weight management in obese or overweight individuals. Its mechanism of action includes enhancing satiety, suppressing appetite, and improving glycemic control. Key Benefits: Significant weight loss; reduced appetite and increased satiety; lower blood glucose levels and improved hemoglobin A1c (HbA1c) levels; improved certain metabolic markers;
10 mg · 10 vialsAvailability on request
AICARKey Benefits of AICAR: Promotes glucose uptake by skeletal muscle, influences energy metabolism, and improves endurance,
50 mg · 10 vialsAvailability on request
AdipotideEffects observed in the Adipotide study: weight and body fat loss, as well as improvements in metabolic markers
2 mg · 10 vialsAvailability on request
SemaglutideSemaglutide belongs to the class of GLP-1 receptor agonists and is primarily used to treat type 2 diabetes and obesity/overweight in specific populations. Its main benefits include: lowering blood glucose levels, suppressing appetite, aiding weight loss, reducing certain cardiovascular risks, and improving metabolic markers
2 mg · 10 vialsAvailability on request
AOD-9604AOD-9604 is a synthetic growth hormone (hGH) fragment peptide that was initially developed to harness the “fat-burning” effects of a portion of growth hormone while avoiding the growth and IGF-1-related effects associated with full-length growth hormone. Its promotional and research focus is on: promoting fat breakdown and fat oxidation, and fat loss/weight loss
2 mg · 10 vialsAvailability on request
MOTS-c (Human)MOTS-c (human MOTS-c) is a 16-amino acid peptide derived from mitochondria and belongs to the class of “mitochondria-derived peptides,” which have become a hot topic of research in recent years. It is associated with energy metabolism, insulin sensitivity, and exercise adaptation. Benefits and Effects: Improves insulin sensitivity and glucose metabolism; influences fat metabolism; promotes exercise adaptation and physical performance; exhibits anti-aging potential;
10 mg · 10 vialsAvailability on request
MazdutideMazdutide is a new-generation weight-loss drug that has garnered significant attention in recent years. Unlike semaglutide, it not only acts on GLP-1 but also simultaneously activates both the GLP-1 receptor and the glucagon receptor (GCG), and is therefore classified as a “dual receptor agonist.” Key benefits: Significant weight loss, reduced appetite, improved blood glucose levels, and improved certain metabolic markers
5 ml · 10 vialsAvailability on request
SurvodutideSuvodypeptide (commonly translated as “Suvodypeptide”) is very similar to Mazdupeptide, which you inquired about previously; it is also a dual agonist of the GLP-1 receptor and the glucagon receptor. Its primary benefits include: weight loss, improved insulin sensitivity and glucose metabolism, reduced liver fat, and potential benefits for MASH and liver fibrosis
10 mg · 10 vialsAvailability on request
CagrilintideCagrilintide is a long-acting amylin analog. It works through a different mechanism than semaglutide: while semaglutide primarily acts on GLP-1, cagrilintide primarily regulates appetite and gastric emptying through the amylin pathway. Main benefits: Reduces appetite, increases feelings of fullness, aids in weight loss, reduces waist circumference, and improves certain metabolic markers
5 mg · 10 vialsAvailability on request
Cagrilintide + SemaglutideThe combination of caglinulin and semaglutide is known as CagriSema. It is currently one of the most promising combinations in the field of weight loss: one acts primarily through the amylin pathway, while the other acts through the GLP-1 pathway, and the two have complementary effects in controlling appetite and weight. Key benefits: It effectively suppresses appetite, promotes significant weight loss, and improves metabolic markers such as blood glucose and blood pressure,
5 mg · 10 vialsAvailability on request
CerebrolysinCerebrolysin is an injectable formulation containing a variety of low-molecular-weight peptides and amino acids, primarily used in certain countries to treat neurological disorders. It is believed to have neurotrophic, neuroplasticity-promoting, and neuroprotective effects. Potential benefits: Stroke rehabilitation, cognitive function, recovery from nerve damage, traumatic brain injury
10 mg · 10 vials
